Compass Therapeutics

Genelux (NASDAQ: GNLX) Stock Quote

Last Trade: US$28.10 -0.90 -3.10
Volume: 15,921
5-Day Change: 20.81%
YTD Change: 66.27%
Market Cap: US$693.230M

Latest News From Genelux

Phase 2 Trial of Olvi-Vec-primed immunochemotherapy in heavily pre-treated patients Met primary endpoint of objective response rate with deep and durable responses Generated promising progression-free survival Demonstrated clinical reversal of platinum resistance and refractoriness Phase 3 OnPrime/GOG-3076 randomized active-controlled registrational trial in collaboration with GOG Foundation/Partners is currently enrolling... Read More
WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of the Company's common stock at a price of $20.00 per share, for gross proceeds of approximately $33 million, before deducting offering expenses payable by Genelux. Proceeds from the private placement, combined with the current... Read More
WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types, today announced that it will ring the Nasdaq Stock Market (“Nasdaq”) opening bell on... Read More
Cue Biopharma